ClinicalTrials.gg
CompletedNCT03641560Updated Jun 24, 2026Results posted

A Safety and Efficacy Study of Enzalutamide in Indian Patients With Progressive Metastatic Castration-Resistant Prostate Cancer (mCRPC) Previously Treated With Docetaxel-Based Chemotherapy

A Phase 4 interventional study of Enzalutamide and Androgen deprivation therapy (ADT) in Metastatic Castration Resistant Prostate Cancer, sponsored by Astellas Pharma Inc. Completed at 8 sites in India. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-24.

Sponsored by Astellas Pharma Inc · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
52
Allocation
Not applicable
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 125 studies testing enzalutamide in Prostatic Neoplasms — 17 open to participants now, 38 under way, 9 of them phase 3. enzalutamide · Prostatic Neoplasms.

Enrollment
63rd of 125
52 · median 52
Started
2018
with 3 others
Phase 4
7 of 125
none open now
Registered
82nd of 125
by date
Lead sponsor
7 of 125
Astellas Pharma Inc

Among the 125 studies testing enzalutamide in Prostatic Neoplasms, this one is the 63rd largest by enrollment, is one of 4 that started in 2018, is one of 7 in phase 4, and was the 82nd registered.

Prostatic Neoplasms

7,051 studies on the registry are indexed under Prostatic Neoplasms; 1,579 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

17 of the 125 studies testing enzalutamide in Prostatic Neoplasms are open now, in 12 countries. Recruiting first, the newest first:

12 more — sign in →

By country, each count listing its studies:

All 17 open studies →

About enzalutamide

enzalutamide: first FDA approval 2012 (XTANDI), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,228 Prostatic Neoplasms studies recruiting now, 927 (75%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 125 studies testing enzalutamide in Prostatic Neoplasms, or all of them as a file.
02

Study summary

The purpose of this study was to evaluate the safety and tolerability of enzalutamide in Indian patients with progressive mCRPC previously treated with docetaxel-based chemotherapy. This study also evaluated the effect of enzalutamide on prostate-specific antigen (PSA).

03

Conditions studied

  • Metastatic Castration Resistant Prostate Cancer

Browse trials for

Keywords

  • Progressive Metastatic Castration-Resistant Prostate Cancer (mCRPC)
  • Enzalutamide
  • Xtandi
  • MDV3100
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject is diagnosed with or cytologically confirmed adenocarcinoma of the prostate without neuroendocrine differentiation, signet cell or small cell histology.
  • Subject with established diagnosis of castration-resistant prostate carcinoma.
  • Subject is being newly initiated on Xtandi treatment (Enzalutamide).
  • Subject has an estimated of ≥ 6 months.
  • Subject agrees not to participate in another interventional study while participating in the present study.

Exclusion criteria

Exclusion Criteria:

  • Subject who is not eligible to receive Xtandi as per the locally approved prescribing information.
  • Subject participating or planning to participate in any interventional drug trial during the course of this trial.
  • Subject has received study within 28 days or 5 half-lives, whichever is longer, prior to screening.
  • Subject has any condition which makes the subject unsuitable for study participation.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
52 participants (actual)

Study arms

  • Experimental
    Enzalutamide

    Participants with progressive mCRPC who had previously been treated with docetaxel-based chemotherapy received 160 milligrams (mg) (4 capsules of 40 mg) enzalutamide orally, once daily until disease progression, unacceptable toxicity or any other discontinuation criteria were met.

    Drug: Enzalutamide · Drug: Androgen deprivation therapy (ADT)

Interventions

  • Enzalutamide was administered orally

    Also known as: MDV3100, Xtandi

  • DrugAndrogen deprivation therapy (ADT)

    All participants were required to maintain ADT during study treatment, either using a Gonadotropin Releasing Hormone (GnRH) agonist/antagonist or having a history of bilateral orchiectomy

06

What researchers measure

Primary outcomes

  1. Number of Participants With Treatment- Emergent Adverse Events (TEAEs)

    An AE was defined as any untoward medical occurrence in a participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An AE could therefore be any unfavorable \& unintended sign (including an abnormal laboratory finding \[e.g. hematology, clinical chemistry, or urinalysis or other safety assessment e.g., ECGs, radiographic scans, vital signs measurements, physical examination\]), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product. TEAE was defined as an adverse event observed after starting administration of the study drug.

    Time frame: From first dose of study drug until 30 days after last dose (Up to 1899 days)

Secondary outcomes

  1. Percentage of Participants With Confirmed Prostate-specific Antigen (PSA) Response

    Confirmed PSA response rate was defined as the percentage of participants with \>= 50% decline in PSA from baseline to the lowest postbaseline PSA result, with a consecutive assessment conducted at least 3 weeks later to confirm the PSA response.

    Time frame: Baseline (Day 1); Days 29, 57, 85, 169 and then every 84 days until 30 days after the last dose (up to Day 1899)

07

Results

Posted Jan 23, 2025

Participant flow

Indian male participants with progressive mCRPC previously treated with docetaxel-based chemotherapy were enrolled in this study.

Participant flow — Overall Study
MilestoneEnzalutamide
Started52
Completed0
Not completed52
Withdrew: Withdrawal by subject6
Withdrew: Progressive disease40
Withdrew: Death6

Outcome measures

PrimaryNumber of Participants With Treatment- Emergent Adverse Events (TEAEs)

An AE was defined as any untoward medical occurrence in a participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An AE could therefore be any unfavorable \& unintended sign (including an abnormal laboratory finding \[e.g. hematology, clinical chemistry, or urinalysis or other safety assessment e.g., ECGs, radiographic scans, vital signs measurements, physical examination\]), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product. TEAE was defined as an adverse event observed after starting administration of the study drug.

Time frame:
From first dose of study drug until 30 days after last dose (Up to 1899 days)
Reported as:
Number · Participants
Number of Participants With Treatment- Emergent Adverse Events (TEAEs)
ParticipantsEnzalutamide
Number of Participants With Treatment- Emergent Adverse Events (TEAEs)36
SecondaryPercentage of Participants With Confirmed Prostate-specific Antigen (PSA) Response

Confirmed PSA response rate was defined as the percentage of participants with \>= 50% decline in PSA from baseline to the lowest postbaseline PSA result, with a consecutive assessment conducted at least 3 weeks later to confirm the PSA response.

Time frame:
Baseline (Day 1); Days 29, 57, 85, 169 and then every 84 days until 30 days after the last dose (up to Day 1899)
Reported as:
Number · Percentage of Participants
Percentage of Participants With Confirmed Prostate-specific Antigen (PSA) Response
Percentage of ParticipantsEnzalutamide
Percentage of Participants With Confirmed Prostate-specific Antigen (PSA) Response46

Adverse events

Collected over From first dose of study drug until 30 days after last dose (Up to 1899 days). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Enzalutamide6/52 (11.5%)10/52 (19.2%)25/52 (48.1%)
Most frequent serious events
Showing 10 of 14
Most frequent serious events
EventEnzalutamide
Respiratory failureRespiratory, thoracic and mediastinal disorders2/52
Cardiac arrestCardiac disorders1/52
Cardio-respiratory arrestCardiac disorders1/52
Myocardial ischaemiaCardiac disorders1/52
AstheniaGeneral disorders1/52
Chest discomfortGeneral disorders1/52
Multiple organ dysfunction syndromeGeneral disorders1/52
Lower respiratory tract infectionInfections and infestations1/52
PneumoniaInfections and infestations1/52
Pain in extremityMusculoskeletal and connective tissue disorders1/52
Most frequent other events
Most frequent other events
EventEnzalutamide
ConstipationGastrointestinal disorders7/52
PainGeneral disorders7/52
Decreased appetiteMetabolism and nutrition disorders7/52
Back painMusculoskeletal and connective tissue disorders7/52
AstheniaGeneral disorders5/52
NauseaGastrointestinal disorders3/52
VomitingGastrointestinal disorders3/52
ArthralgiaMusculoskeletal and connective tissue disorders3/52
Pain in extremityMusculoskeletal and connective tissue disorders3/52

Baseline characteristics

Safety Analysis Set (SAF): The SAF consisted of all participants who took at least 1 dose of study drug, and was used for safety analyses.

Age, Continuous
Age, Continuous(Years)Enzalutamide
Mean66.5 ± 8.4
Sex: Female, Male
Sex: Female, Male(Participants)Enzalutamide
Female0
Male52
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Enzalutamide
Hispanic or Latino3
Not Hispanic or Latino43
Unknown or Not Reported6
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Enzalutamide
American Indian or Alaska Native0
Asian52
Native Hawaiian or Other Pacific Islander0
Black or African American0
White0
More than one race0
Unknown or Not Reported0
08

Study locations

8 sites
  • Site IN00002
    Ahmedabad, India
  • Site IN00004
    Hubli, India
  • Site IN00008
    Kolkata, India
  • Site IN00003
    Nashik, India
  • Site IN00007
    Nashik, India
  • Site IN00010
    New Delhi, India
  • Site IN00001
    Pune, India
  • Site IN00011
    Surat, India
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — Access to anonymized individual participant level data collected during the study, in addition to study-related supporting documentation, is planned for studies conducted with approved product indications and formulations, as well as products terminated during development. Studies conducted with product indications or formulations that remain active in development are assessed after study completion to determine if Individual Participant Data can be shared. Further details on Astellas' data sharing policy can be found at https://www.clinicaltrials.astellas.com/transparency/.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2018 to primary completion in Feb 2024, 65 months.

Results were first posted in Jan 2025, 11 months after primary completion.

Of 52 phase 4 interventional studies under Prostatic Neoplasms, half reached primary completion within 41 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 67. This study's 65 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 20, 2018
First posted
Aug 22, 2018
StartActual
Sep 19, 2018
Primary completionActual
Feb 20, 2024
CompletionActual
Feb 20, 2024
Results first posted
Jan 23, 2025
Last update
Jun 24, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 24, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03641560
Responsible party
Sponsor
First posted
Aug 22, 2018
Start date
Sep 19, 2018
Primary completion
Feb 20, 2024
Completion
Feb 20, 2024
Results posted
Jan 23, 2025
Last update
Jun 24, 2026

Study contacts

Central Contact
study director · Astellas Pharma Inc

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Enzalutamide

Start the discussion